Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 100 /hr
Hire Dr. Khalid S.
United Kingdom
USD 100 /hr

Expert in CRISPR/Cas9, molecular and cell biology, organoid, immunology, precision cancer research

Profile Summary
Subject Matter Expertise
Services
Writing Technical Writing
Research User Research, Scientific and Technical Research
Consulting Healthcare Consulting, Scientific and Technical Consulting
Data & AI Data Visualization
Work Experience

Senior Scientist

Cancer Research UK Cambridge Research Institute

September 2019 - Present

Researcher

Helsingin Yliopisto

February 2018 - August 2019

Postdoctoral Fellow

University of Helsinki

January 2018 - August 2019

Education

PhD (Institute for Molecular Medicine Finland FIMM)

University of Helsinki

March 2010 - August 2018

Certifications
  • Certification details not provided.
Publications
PREPRINT
Khalid Saeed, Jun Dai, Shuyu Zheng, Matías M. Falco, Jie Bao, Johanna Eriksson, Fernando Perez-Villatoro, Anniina Färkkilä, Olli Dufva, Satu Mustjoki, et al. (2022). Tracing back primed resistance in cancer via sister cells .
JOURNAL ARTICLE
Khalid Saeed, Poojitha Ojamies, Teijo Pellinen, Samuli Eldfors, Riku Turkki, Johan Lundin, Petrus Järvinen, Harry Nisen, Kimmo Taari, Taija M. af Hällström, et al.(2019). Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells . International Journal of Cancer. Wiley
Androgen receptor‐interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen‐deficient conditions.
comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancers.